Novavax: Promising Pipeline And Stable Revenue Add To Upside
- Novavax has a strong clinical pipeline with multiple vaccines that have great potential.
- The company aims to establish approaches in order to better prepare for and more effectively respond to fast-spreading infections.
- Novavax's annual revenue grew 62-fold over the last five years; its revenue grew 92% in 4Q13. For full-year 2014, revenue is expected to grow 77.7%.
- The recently extended HHS BARDA contract provides a stable revenue source for the company.